State of New Jersey Common Pension Fund D Purchases 5,803 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

State of New Jersey Common Pension Fund D boosted its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 16.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 40,341 shares of the company’s stock after purchasing an additional 5,803 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in CRISPR Therapeutics were worth $1,895,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. ProShare Advisors LLC lifted its position in CRISPR Therapeutics by 10.1% during the 1st quarter. ProShare Advisors LLC now owns 5,791 shares of the company’s stock valued at $395,000 after acquiring an additional 530 shares during the period. Vanguard Group Inc. grew its stake in shares of CRISPR Therapeutics by 2.9% in the 1st quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company’s stock worth $111,564,000 after buying an additional 46,148 shares during the last quarter. Axxcess Wealth Management LLC increased its position in CRISPR Therapeutics by 10.0% during the 1st quarter. Axxcess Wealth Management LLC now owns 9,945 shares of the company’s stock valued at $678,000 after buying an additional 905 shares in the last quarter. Advisors Asset Management Inc. raised its stake in CRISPR Therapeutics by 42.3% during the first quarter. Advisors Asset Management Inc. now owns 9,462 shares of the company’s stock valued at $645,000 after buying an additional 2,814 shares during the last quarter. Finally, Capital Group Investment Management PTE. LTD. boosted its holdings in CRISPR Therapeutics by 32.3% in the first quarter. Capital Group Investment Management PTE. LTD. now owns 26,581 shares of the company’s stock worth $1,812,000 after acquiring an additional 6,485 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Chardan Capital lowered their price target on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a report on Thursday, November 7th. Rodman & Renshaw assumed coverage on shares of CRISPR Therapeutics in a report on Friday, August 2nd. They issued a “buy” rating and a $90.00 price objective for the company. Royal Bank of Canada reissued a “sector perform” rating and issued a $53.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $74.94.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock opened at $47.30 on Tuesday. The stock’s fifty day moving average is $47.88 and its 200 day moving average is $52.02. CRISPR Therapeutics AG has a one year low of $43.42 and a one year high of $91.10. The stock has a market cap of $4.04 billion, a P/E ratio of -16.71 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. The firm had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same period in the previous year, the firm earned ($1.41) EPS. Analysts predict that CRISPR Therapeutics AG will post -5.2 EPS for the current year.

Insiders Place Their Bets

In related news, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the sale, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. This trade represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Samarth Kulkarni sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $55.62, for a total value of $1,668,600.00. Following the completion of the transaction, the chief executive officer now directly owns 196,540 shares in the company, valued at approximately $10,931,554.80. This represents a 13.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 35,382 shares of company stock worth $1,917,679 over the last three months. 4.10% of the stock is currently owned by company insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.